» Articles » PMID: 15466207

Cdc7 Inhibition Reveals a P53-dependent Replication Checkpoint That is Defective in Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Oct 7
PMID 15466207
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Cdc7 is an evolutionarily conserved kinase that regulates S phase by promoting replication origin activation. Down-regulation of Cdc7 by small interfering RNA in a variety of tumor cell lines causes an abortive S phase, leading to cell death by either p53-independent apoptosis or aberrant mitosis. Unlike replication fork blockade, Cdc7-depleted tumor cells do not elicit a robust checkpoint response; thus, inhibitory signals preventing additional cell cycle progression are not generated. In normal fibroblasts, however, a p53-dependent pathway actively prevents progression through a lethal S phase in the absence of sufficient Cdc7 kinase. We show that in this experimental system, p53 is required for the lasting maintenance of this checkpoint and for cell viability. With this work we reveal and begin to characterize a novel mechanism that regulates DNA synthesis in human cells, and we suggest that inhibition of Cdc7 kinase represents a promising approach for the development of a new generation of anticancer agents.

Citing Articles

Synthetic lethal strategies for the development of cancer therapeutics.

Ngoi N, Gallo D, Torrado C, Nardo M, Durocher D, Yap T Nat Rev Clin Oncol. 2024; 22(1):46-64.

PMID: 39627502 DOI: 10.1038/s41571-024-00966-z.


Starting DNA Synthesis: Initiation Processes during the Replication of Chromosomal DNA in Humans.

Nasheuer H, Meaney A Genes (Basel). 2024; 15(3).

PMID: 38540419 PMC: 10969946. DOI: 10.3390/genes15030360.


Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner.

Kim S, Maric C, Briu L, Fauchereau F, Baldacci G, Debatisse M Int J Mol Sci. 2023; 24(13).

PMID: 37445805 PMC: 10341899. DOI: 10.3390/ijms241310629.


Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.

Kuboki Y, Shimizu T, Yonemori K, Kojima T, Kondo S, Koganemaru S Cancer Res Commun. 2023; 2(11):1426-1435.

PMID: 36970056 PMC: 10035389. DOI: 10.1158/2767-9764.CRC-22-0277.


Bioinformatics analysis of the prognostic biomarkers and predictive accuracy of differentially expressed genes in high-risk multiple myeloma based on Gene Expression Omnibus database mining.

Du C, Guo D, Zhang Y, Gao C, Bai J Ann Transl Med. 2023; 10(24):1325.

PMID: 36660705 PMC: 9843371. DOI: 10.21037/atm-22-2656.